GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2010

Fibrocell and Meifu Establish JV to Develop and Market Autologous Cell Therapies in Asia

  • Cell therapies specialist Fibrocell Science and Chinese firm Hefei Meifu Bio-Tech are establishing a joint venture called Fibrocell Science Asia to develop and market autologous fibroblast therapies in Asia (excluding Japan). Under the terms of the deal, Fibrocell will provide access to its relevant IP, clinical data, and manufacturing processes. Meifu will shoulder all costs associated with construction and operation of a cGMP manufacturing facility in Hefei along with commercialization and ongoing operational and R&D expenses.

    “In Asia the health and beauty markets are expanding rapidly, which we believe will offer significant opportunity for autologous cellular therapy as a natural and personalized product,” comments Zhou Tau, chairman of the new joint venture.

    Fibrocell is focused on the development of autologous fibroblast regenerative therapies for both medical and aesthetic indications. The firm’s lead product, for the treatment of moderate to severe nasolabial fold wrinkles, is currently undergoing BLA review by FDA. Regenerative cell products for periodontal applications and for the treatment of acne scars and restrictive burn scars are currently in Phase II development.

    Meifu develops, manufactures, and distributes pharmaceutical anticancer intermediates and APIs along with generic drugs including paclitaxel and docetaxel.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?